GEPIA 3
GEPIA3 introduces innovative modules that enhance analytical capabilities, including:
- a) a comprehensive drug sensitivity analysis that integrates patient-derived data from TCGA with cell-line screening data for over 1,000 therapeutic agents,
- b) offering advanced analyses of gene/protein interactions, as well as regulatory networks across multiple cancer types,
- c) incorporating RNA alterations—such as allele-specific expression, alternative promoters and RNA fusions—based on Pan-Cancer Analysis of Whole Genomes (PCAWG) project,
How to cite GEPIA 3
Yujian Kang, Lingjie Pan, Yiyu Liu, Zhengqin Rong, Jiaxi Liu, Fenglin Liu*. GEPlA3: Enhanced Drug Sensitivity and Interaction Network Analysis for Cancer Research. Nucleic Acids Research, 2025.
Contact us
If any question about the GEPIA3, please contact us: lfl@pku.edu.cn
Acknowledgement
The RNA-Seq datasets GEPIA3 used is based on the UCSC Xena project ( http://xena.ucsc.edu ), which are computed by a standard pipeline.
This project was supported by Fundamental Research Funds for the Central Universities [grant number 2024CDJYXTD-010] and Peking University Undergraduate Teaching Reform Funding [grant number JG2025013].
License Statement: All content on this website is freely available to all users, including for commercial use.